Skip to main content
Virbac logo

Virbac — Investor Relations & Filings

Ticker · FR000 ISIN · FR0000031577 LEI · 969500QQ1X5XHG649644 PA Manufacturing
Open in API
Filings indexed 975 across all filing types
Latest filing 2014-11-05 Declaration of Voting R…
Country FR France
Listing PA FR000

About Virbac

https://corporate.virbac.com/home.html

Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Founded in 1968 by a veterinarian, the company provides veterinarians, farmers, and pet owners with a comprehensive range of products and services. Its portfolio of innovative solutions covers the majority of animal species and diseases, with a focus on both companion and farm animals. Key product areas include vaccines, dermatology, parasite control, dental care, nutrition, and diagnostics. Through its international R&D network, Virbac develops solutions to prevent, diagnose, and treat animal pathologies, contributing to animal welfare and supporting sustainable farming.

Recent filings

Filing Released Lang Actions
Declaration of the nb of shares and voting rights Oct.14
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled 'DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS' and explicitly references regulatory requirements from the French Financial Market Authority (Autorité des Marchés Financiers). It provides a table detailing the total number of shares and the total number of voting rights as of a specific date (October 31, 2014). This content directly relates to the official declaration of voting rights and share capital structure, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). It is not an AGM presentation, a full annual report, or a management change announcement.
2014-11-05 English
Déclaration d'actions et de droits de vote au 31 Octobre 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION D'ACTIONS ET DE DROITS DE VOTE" (Declaration of Shares and Voting Rights) and explicitly references Article 223-16 of the AMF General Regulation. It presents a table detailing the total number of shares and the total gross and net voting rights as of a specific date (October 31, 2014). This content directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or related voting rights disclosures.
2014-11-05 French
Virbac agrees to acquire veterinary assets from Eli Lilly in the US
M&A Activity Classification · 98% confidence The document text explicitly announces an agreement by Virbac to acquire veterinary assets from Eli Lilly in the United States, detailing the specific products (Sentinel®Flavor Tabs and Sentinel® Spectrum) and the context (related to Eli Lilly's acquisition of Novartis Animal Health and FTC review). This content describes a significant corporate transaction involving mergers, acquisitions, or divestitures. Based on the provided definitions, the most appropriate category is 'M&A Activity' (Code: TAR), which covers merger proposals or takeover bids, encompassing major asset acquisitions.
2014-10-27 English
Virbac prêt à acquérir des actifs vétérinaires d'Eli Lilly aux USA
M&A Activity Classification · 98% confidence The document is a press release dated October 27, 2014, announcing that Virbac has signed an agreement to acquire specific veterinary assets (Sentinel® Flavor Tabs and Sentinel® Spectrum) from Eli Lilly in the United States, contingent on the FTC's approval related to Eli Lilly's acquisition of Novartis Animal Health. This clearly describes a proposed merger or acquisition activity. Based on the definitions, this falls under 'M&A Activity' (Code: TAR). The document is a detailed announcement, not just a notification of a report's publication.
2014-10-27 French
VIRBAC : confirmation de rebond de croissance au troisième trimestre
Earnings Release Classification · 98% confidence The document is a press release dated October 16, 2014, titled "Virbac : confirmation du rebond de croissance au troisième trimestre" (Virbac: confirmation of growth rebound in the third quarter). It explicitly reports consolidated revenue figures for the third quarter (202.7 M€) and the cumulative nine-month period (569.0 M€), along with key growth metrics at constant currency and scope. This content structure—a brief announcement highlighting key financial results for a specific period (Q3 and 9 months)—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial, high-level announcement of those results. 9M 2014
2014-10-16 French
VIRBAC : confirmation of the rebound of growth in the third quarter
Earnings Release Classification · 99% confidence The document is a public release dated October 16th, 2014, detailing Virbac's consolidated sales for the third quarter and year-to-date (nine months) of 2014. It provides key financial figures, growth rates (absolute, constant parity, organic), and segment performance analysis. This content structure—a brief announcement focusing on period-end financial highlights rather than a comprehensive annual filing (10-K) or a detailed management discussion (MDA)—is characteristic of an Earnings Release (ER). It is not a full report, a transcript, or a presentation. 9M 2014
2014-10-16 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.